Ani Pharmaceuticals [ANIP] vs Zoetis [ZTS] Detailed Stock Comparison

Ani Pharmaceuticals Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Ani Pharmaceuticals Inc. wins in 8 metrics, Zoetis Inc. wins in 12 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Ani Pharmaceuticals Inc. Zoetis Inc. Better
P/E Ratio (TTM) 24.08 19.58 Zoetis Inc.
Price-to-Book Ratio 3.10 15.04 Ani Pharmaceuticals Inc.
Debt-to-Equity Ratio 116.19 279.59 Ani Pharmaceuticals Inc.
PEG Ratio -0.07 2.81 Zoetis Inc.
EV/EBITDA 11.46 13.96 Ani Pharmaceuticals Inc.
Profit Margin (TTM) 8.87% 28.24% Zoetis Inc.
Operating Margin (TTM) 11.99% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 11.99% 34.69% Zoetis Inc.
Return on Equity 16.16% 65.99% Zoetis Inc.
Return on Assets (TTM) 3.82% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $150.90M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 33.70% -53.93% Ani Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 2.06 5.26 Ani Pharmaceuticals Inc.
Enterprise Value $2.00B $56.75B Zoetis Inc.
EV/Revenue Ratio 2.27 6.00 Ani Pharmaceuticals Inc.
Gross Profit Margin (TTM) 59.42% 70.17% Zoetis Inc.
Revenue per Share (TTM) $44 $21 Ani Pharmaceuticals Inc.
Earnings per Share (Diluted) $3.32 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.44 0.97 Ani Pharmaceuticals Inc.
Short % of Float 19.22% 4.06% Zoetis Inc.

Ani Pharmaceuticals Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

ANIP
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Ani Pharmaceuticals Inc.0.78%-7.99%-8.61%-1.14%-9.00%-4.08%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Ani Pharmaceuticals Inc.33.70%63.56%128.36%43.87%-27.55%-28.50%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: Ani Pharmaceuticals Inc. vs Zoetis Inc.

MetricANIPZTS
Market Information
Market Cap i$1.78B$49.75B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i380,5352,727,710
90 Day Avg. Volume i370,6183,835,940
Last Close$75.23$167.10
52 Week Range$59.61 - $99.50$139.70 - $200.33
% from 52W High-24.39%-16.59%
All-Time High$450.00 (May 29, 2000)$249.27 (Dec 27, 2021)
% from All-Time High-83.28%-32.96%
Growth Metrics
Quarterly Revenue Growth0.30%0.03%
Quarterly Earnings Growth0.30%0.04%
Financial Health
Profit Margin (TTM) i0.09%0.28%
Operating Margin (TTM) i0.12%0.35%
Return on Equity (TTM) i0.16%0.66%
Debt to Equity (MRQ) i116.19279.59
Cash & Liquidity
Book Value per Share (MRQ)$25.81$7.84
Cash per Share (MRQ)$14.12$5.48
Operating Cash Flow (TTM) i$185.22M$2.90B
Levered Free Cash Flow (TTM) i$119.42M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Ani Pharmaceuticals Inc. vs Zoetis Inc.

MetricANIP (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i24.0819.58
Forward P/E i7.5515.61
PEG Ratio i-0.072.81
Price to Sales (TTM) i2.065.26
Price to Book (MRQ) i3.1015.04
Market Capitalization
Market Capitalization i$1.78B$49.75B
Enterprise Value i$2.00B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i2.276.00
Enterprise to EBITDA i11.4613.96
Risk & Other Metrics
Beta i0.440.97
Book Value per Share (MRQ) i$25.81$7.84

Financial Statements Comparison: Ani Pharmaceuticals Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricANIP (2025)ZTS (2025)
Revenue/Sales i883.37M9.47B
Cost of Goods Sold i341.31M2.67B
COGS % of Revenue i38.6%28.2%
Gross Profit i542.06M6.80B
Gross Margin i61.4%71.8%
Research & Development i51.66M698.00M
Operating Income (EBIT) i81.23M3.60B
Operating Margin i9.2%38.0%
EBITDA i174.58M4.17B
EBITDA Margin i19.8%44.1%
Pre-Tax Income i95.79M3.36B
Pre-Tax Income % of Revenue i10.8%35.5%
Income Tax i17.45M687.00M
Income Tax % of Revenue i2.0%7.3%
Net Income (Profit) i78.34M2.67B
Profit Margin i8.9%28.2%

Balance Sheet & Liquidity Metrics

MetricANIP (2025)ZTS (2025)
Cash & Equivalents i285.59M2.31B
Total Current Assets i753.12M6.77B
Total Current Assets % of Revenue i85.3%71.5%
Total Current Liabilities i278.11M2.24B
Total Current Liabilities % of Revenue i31.5%23.6%
Long-Term Debt i599.77M9.24B
Long-Term Debt % of Revenue i67.9%97.6%
Total Shareholders Equity i540.72M3.33B
Retained Earnings i-23.10M13.74B
Retained Earnings % of Revenue i-2.6%145.2%
Property, Plant & Equipment i650,000288.00M

Cash Flow Statement Comparison

MetricANIP (2025)ZTS (2025)
Operating Cash Flow i139.39M2.78B
Operating Cash Flow % of Revenue i15.8%29.3%
Capital Expenditures i-13.84MN/A
Free Cash Flow i150.90M2.28B
FCF Margin i17.1%24.1%
Debt Repayment i-10.16M-1.35B
Common Stock Repurchase i-12.21M-3.24B

Short Interest & Institutional Ownership Analysis

MetricANIPZTS
Shares Short i3.58M15.12M
Short Ratio i9.943.60
Short % of Float i19.22%4.06%
Shares Outstanding i22.49M424.93M
Float Shares i19.34M421.29M
% Held by Insiders i7.37%0.15%
% Held by Institutions i99.81%101.50%
% Held by Public i-7.18%-1.65%

Dividend Analysis & Yield Comparison: Ani Pharmaceuticals Inc. vs Zoetis Inc.

MetricANIPZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026